BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology AssetsBullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready...
The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 AgonistIn December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to...
AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal DiseaseBirmingham, Alabama, and London, England, 1 September 2022 – AeroNeph Therapeutics (“AeroNeph”; www.aeroneph.com), a pioneer in discovery...
Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMedSee full Press Release by clicking the link below!